Aratana Therapeutics, Inc. (NASDAQ: PETX) 22.4% HIGHER; announced positive results from its pivotal field study of AT-001 (Grapiprant), the company’s innovative drug for treating pain in dogs with osteoarthritis. In the study, dogs receiving AT-001 demonstrated improvements in pain assessment scores that were statistically significant compared to placebo (p
NQ Mobile (NYSE: NQ) 14.3% HIGHER; reported Q3 EPS of ($0.19), versus ($0.04) reported last year. Revenue for the quarter came in at $81.2 million, versus $54.2 million reported last year. Tack